Cargando…

Tumor‐infiltrating CD8(+) T cell is prognostic and predicts adjuvant chemotherapy benefit in patients with limited‐stage small cell esophageal carcinoma

Detalles Bibliográficos
Autores principales:	Zhang, Zhihui, Zhang, Chaoqi, Zhang, Guochao, Luo, Yuejun, Xue, Liyan, Zeng, Qingpeng, Wu, Peng, Wang, Lide, Sun, Nan, He, Jie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Letter to Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8236121/ https://www.ncbi.nlm.nih.gov/pubmed/34185404 http://dx.doi.org/10.1002/ctm2.456

Ejemplares similares

Tumor Necrosis Factor Family Member Profile Predicts Prognosis and Adjuvant Chemotherapy Benefit for Patients With Small-Cell Lung Cancer
por: Zhang, Zhihui, et al.
Publicado: (2021)

m(6)A regulator expression profile predicts the prognosis, benefit of adjuvant chemotherapy, and response to anti-PD-1 immunotherapy in patients with small-cell lung cancer
por: Zhang, Zhihui, et al.
Publicado: (2021)

m(6)A regulators as predictive biomarkers for chemotherapy benefit and potential therapeutic targets for overcoming chemotherapy resistance in small-cell lung cancer
por: Zhang, Zhihui, et al.
Publicado: (2021)

Costimulatory molecule expression profile as a biomarker to predict prognosis and chemotherapy response for patients with small cell lung cancer
por: Wu, Peng, et al.
Publicado: (2022)

An immune-related lncRNA signature predicts prognosis and adjuvant chemotherapeutic response in patients with small-cell lung cancer
por: Zhang, Zhihui, et al.
Publicado: (2021)

The landscape of m(6)A regulators in small cell lung cancer: molecular characteristics, immuno-oncology features, and clinical relevance
por: Zhang, Chaoqi, et al.
Publicado: (2021)

Comprehensive analyses of N (6)‐methyladenosine‐related long noncoding RNA profiles with prognosis, chemotherapy response, and immune landscape in small cell lung cancer
por: Luo, Yuejun, et al.
Publicado: (2022)

Identification of a Prognostic Immune Signature for Esophageal Squamous Cell Carcinoma to Predict Survival and Inflammatory Landscapes
por: Zhang, Chaoqi, et al.
Publicado: (2020)

The combination of novel immune checkpoints HHLA2 and ICOSLG: A new system to predict survival and immune features in esophageal squamous cell carcinoma
por: Zhang, Chaoqi, et al.
Publicado: (2020)

RNA N (6)‐methyladenosine modification in the lethal teamwork of cancer stem cells and the tumor immune microenvironment: Current landscape and therapeutic potential
por: Zhang, Zhihui, et al.
Publicado: (2021)

A three‐lncRNA signature of pretreatment biopsies predicts pathological response and outcome in esophageal squamous cell carcinoma with neoadjuvant chemoradiotherapy
por: Zhang, Chaoqi, et al.
Publicado: (2020)

An individualized immune signature of pretreatment biopsies predicts pathological complete response to neoadjuvant chemoradiotherapy and outcomes in patients with esophageal squamous cell carcinoma
por: Zhang, Chaoqi, et al.
Publicado: (2020)

Comprehensive molecular analyses of a TNF family-based signature with regard to prognosis, immune features, and biomarkers for immunotherapy in lung adenocarcinoma
por: Zhang, Chaoqi, et al.
Publicado: (2020)

Identification of a costimulatory molecule-based signature for predicting prognosis risk and immunotherapy response in patients with lung adenocarcinoma
por: Zhang, Chaoqi, et al.
Publicado: (2020)

High infiltration of mast cells is associated with improved response to adjuvant chemotherapy in gallbladder cancer
por: Bo, Xiaobo, et al.
Publicado: (2020)

Adjuvant chemotherapy does not benefit patients with esophageal squamous cell carcinoma treated with definitive chemoradiotherapy
por: Chen, Mingqiu, et al.
Publicado: (2018)

A novel immune checkpoints-based signature to predict prognosis and response to immunotherapy in lung adenocarcinoma
por: Sun, Nan, et al.
Publicado: (2022)

Tumor-infiltrating CD8+ T cells combined with tumor-associated CD68+ macrophages predict postoperative prognosis and adjuvant chemotherapy benefit in resected gastric cancer
por: Lu, Jun, et al.
Publicado: (2019)

Adjuvant immunotherapy in resected esophageal squamous cell carcinoma: a gospel to the non-pCRs
por: Zhang, Zhihui, et al.
Publicado: (2021)

A novel prognostic model: which group of esophageal squamous cell carcinoma patients could benefit from adjuvant chemotherapy
por: Zhou, Zihao, et al.
Publicado: (2022)

CD103(+) tumor-infiltrating lymphocytes predict favorable prognosis in patients with esophageal squamous cell carcinoma
por: Chu, Yifan, et al.
Publicado: (2019)

The Role of Adjuvant Chemotherapy in the Treatment of Esophageal Squamous Cell Carcinoma after Neoadjuvant Chemotherapy
por: Li, Keting, et al.
Publicado: (2023)

Immunoscore Signature Predicts Postoperative Survival and Adjuvant Chemotherapeutic Benefits in Esophageal Squamous Cell Carcinoma
por: Zhuge, Lingdun, et al.
Publicado: (2020)

Adjuvant chemotherapy with paclitaxel and cisplatin in lymph node-positive thoracic esophageal squamous cell carcinoma
por: Zhang, Liangze, et al.
Publicado: (2017)

Tumor-Infiltrating CD4+ Lymphocytes Predict a Favorable Survival in Patients with Operable Esophageal Squamous Cell Carcinoma
por: Chen, Kaiyan, et al.
Publicado: (2017)

Short-term response might influence the treatment-related benefit of adjuvant chemotherapy after concurrent chemoradiotherapy for esophageal squamous cell carcinoma patients
por: Liu, Ao, et al.
Publicado: (2021)

PMN‐MDSCs‐induced accumulation of CD8+CD39+ T cells predicts the efficacy of chemotherapy in esophageal squamous cell carcinoma
por: Qin, Guohui, et al.
Publicado: (2020)

Efficacy of postoperative adjuvant chemotherapy for esophageal squamous cell carcinoma: A meta‐analysis
por: Zhao, Peiliang, et al.
Publicado: (2018)

Adjuvant chemotherapy in node‐positive patients after esophagectomy for esophageal squamous cell carcinoma
por: Jeon, Yeong Jeong, et al.
Publicado: (2023)

Survival Benefit of Adjuvant Chemotherapy in Pulmonary Carcinoid Tumors
por: Sobash, Philip T., et al.
Publicado: (2022)

High Infiltration of CD68(+)/CD163(−) Macrophages Is an Adverse Prognostic Factor after Neoadjuvant Chemotherapy in Esophageal and Gastric Adenocarcinoma
por: Svensson, Maria C., et al.
Publicado: (2022)

S100A7 as a potential diagnostic and prognostic biomarker of esophageal squamous cell carcinoma promotes M2 macrophage infiltration and angiogenesis
por: Lu, Zhiliang, et al.
Publicado: (2021)

ID1 expressing macrophages support cancer cell stemness and limit CD8(+) T cell infiltration in colorectal cancer
por: Shang, Shuang, et al.
Publicado: (2023)

Involvement of Indoleamine 2,3-Dioxygenase in Impairing Tumor-Infiltrating CD8(+) T-Cell Functions in Esophageal Squamous Cell Carcinoma
por: Zhang, Ge, et al.
Publicado: (2011)

Development and validation of a nomogram for predicting survival in patients with surgically resected lung invasive mucinous adenocarcinoma
por: Zhang, Guochao, et al.
Publicado: (2021)

Adjuvant chemotherapy for lymph node positive esophageal squamous cell cancer: The prediction role of low mean platelet volume
por: Liu, Xiaoling, et al.
Publicado: (2022)

Preoperative Splenic Density for the Prediction of Survival and Adjuvant Chemotherapy Benefits in Gastric Cancer
por: Zhang, Wei-teng, et al.
Publicado: (2020)

Polo-like kinase 2 promotes chemoresistance and predicts limited survival benefit from adjuvant chemotherapy in colorectal cancer
por: Xie, Yuquan, et al.
Publicado: (2018)

Association of Tumor-Associated Collagen Signature With Prognosis and Adjuvant Chemotherapy Benefits in Patients With Gastric Cancer
por: Chen, Dexin, et al.
Publicado: (2021)

Clinical response to chemoradiotherapy in esophageal carcinoma is associated with survival and benefit of consolidation chemotherapy
por: Zhao, Zongxing, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_mdmqfcqvlnj4dpej45vjeb800e